Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial.

J Am Heart Assoc · 2014 · PMC4338730 · PMID 25404192

Europe PMC DOI

hedged sentences

0.0080

closest p · 0.2× alpha

0.0080

boldest claim

The sentences

nominally significantP =0.008actually significant

Adjusting for baseline characteristics yielded a 12% reduction in risk of death or nonfatal cardiovascular events (relative hazard 0.88, 95% CI 0.79 to 0.97) that was nominally significant ( P =0.008).

also in 7,732 other papers

did not reach statistical significanceno p-value reported

Patients randomized to cinacalcet experienced fewer nonatherosclerotic cardiovascular events (adjusted relative hazard 0.84, 95% CI 0.74 to 0.96), while the effect of cinacalcet on atherosclerotic events did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.